today. and Vince. you Thanks, us Good for thank joining afternoon, everyone,
Arrowhead Curt and the Scientific role Javier Martin, members us by Officer, the Chief joins San in start who I want management welcoming who Dr. team, joined Bradshaw, newest of Medical to the Chief Officer. as us Dr. of
after to Dr. retiring seasoned leaders also to transitions will Javier a who the and talented We on Curt. also Bruce He to will important are you May want years. as biopharma months role these current to during remain the has Bruce been him May asset needed. six decade I for Given, continue say he an to X, thank XXXX. company and to industry over to retirement. wish as almost role his in be for very Arrowhead fortunate the team. agreed the advisory his an XX has the on in X, over responsibilities He to best next and have all We
we've innovative that we the best-in-class enormously execution. speed business is to address our opportunities numerous to the demonstrated develop growing and can we again that we last have progress and flexible and have Arrowhead's platform an and is year, apart. differences to new turning Now commitment once important over made our lot consistently technology medicines for is achieve biotech But of think be any medical really success. innovation do in guarantee alone sets what company. potentially unwavering This opportunity lives. place enviable conditions a make not and to us We TRiM people's in and
owned wholly the in candidates TRiM-enabled five now clinic, and of partnered. two are are three There which are
studies studies candidates in XXXX. additional and by three plan of two cell clinical be end we next filings month, to intend different we to by end have four regulatory XX XXXX, we types. submit in to clinical TRiM-enabled the the targeting Further, for of Over candidates, pivotal the expect
in believe position size. for unique a company is for sink moment. this Let our strikingly We that all a a
to these ultimate believe aggressive about programs We ability success these confident for a good of achieve of reason to in number and the reasons. have feel our targets clinical we
over mind have in First, have technology platform. XXX TRiM with doses increasingly an the Keep in validated we been people TRiM-enabled XXX treated of that candidates. over
activity programs. see safety We profile a very and all in good benign continued to
focused select phenotypes. gene accepted a clinical the studies without you targets. to to targets if target well-validated will prior biology community words, there can the widely our We other we no we where Second, tend minimize and genetic is knock down, on target that scientific in there leverage risk. benefits belief negative be In
knowledge of and targets data [indiscernible] body we expanding published the ever-expanding will sets, interesting believe an to on new With continue genetics, emerge.
age. to we treat and two golden This Third, what of believe a modality to field accepted the be study beginning, it and decades increasingly diseases intensive development. variety of is is a as reliable RNAi just way powerful after
While RNAi direct was delivery conjugation unlocking the RNAi the of the took value potential potential growing validation of is broader and us by to longer. clear XXXX, and scarcity increasing of of amid we bringing confidence think of We backdrop Company's regard. years the therapeutically outside it related a leveraging of in are scarcity RNAi near-absolute capable to ahead anyone and else liver. this of Interestingly, probably
process R&D shave even discussed months of the off that Day constantly weeks we and Arrowhead finding traditional development days, R&D all waste as is a seen tried level last before. and efficiency innovative been We the not out take regulatory and at our we has month, and to cycle. time ever of demonstrated cutting think Lastly, of sacrificing we without corners, effectively or have speed ways of to the quality
powerful squeezing we uses risk while development idea, programs. more upside So the and at technology, expanding potential are our time indeed. is out of once of and more and the This a
development into our month, last of Day some detail R&D our programs. about several went we During
candidates, patients validation targets. the syndrome in a ANGPTLX as two, We metabolic are that to relative that of at large. dyslipidemias, outcomes and powerful treatment hypercholesterolemia I'll angiopoietin-like being result developed developed protein development -- At ARO-APOCX these genetic for diseases. mutations being APOCX targeting or C-III we of apolipoprotein believe for chylomicronemia the review ARO-ANGX and very improved familial and as cardiovascular being loss-of-function severe X strong discussed cardiometabolic event, is one population the or targeting potential homozygous FCS; HoFH, such in quick day. the our a or treatment There give hypertriglyceridemia two familial now with
these loss been from means adverse clinic with resulting the agents Importantly, targets of other points with the validation. mutations also symptoms any gives using of have the which which associated confidence or in phenotypes, has disease demonstrated likely us nobody multiple protein. the loss-of-function have not demonstrated reported This that been is other mechanisms,
compounds our for support that Phase new data at patients. to studies vulnerabilities, have will but these positioning thrilled addition, Bruce other plans an we Phase will as believe thus presented In with ARO-ANGX, and on X that we recently in that potential say option discuss AHA ARO-APOCX believe results reduce studies we using clinical X from that XXXX. mechanisms initiate they important strongly specific the I and to have proteins RNAi some our far been
We've has seen with deep ARO-ANGX pancreatitis. in conditions, opportunities. as of conditions, more FCS, single regulatory as well ARO-APOCX and such leading are associated with greater reductions to those there doses treat as triglycerides triglycerides and patients elevated believe even clear rare optionality and after pathways relatively to common
patients. liver expect LDL variety We we to study are and it the potential decrease huge fat. cholesterol, that and previous sensitivity Together, expect triglycerides and believe treat to it a to of these ARO-ANGX opportunities could large we in improve insulin lower has suggest
accumulated developed a alpha-X mutant order protein, to covered of hepatocytes for liver, rare associated in in the disease therapeutic possibly We antitrypsin second-generation Z-AAT is RNAi progression or potentially gene damage ARO-AAT, even ARO-AAT repeated also a silencing genetic prevent reverse deficiency, our the as treatment production AAT protein liver cycles by disorder. being to the Z-AAT in the accumulation designed subcutaneously-administered of reduce which with is of fibrosis. clearance of cellular liver the and prevent of prevent allow
ARO-AAT our that studies preclinical normal the clinical effect PiZ quantitation, of AAT led treatment long supports X even with limit ultra-structure. In dosing. serum to in hepatocyte quarterly In or to less levels RNAi a down reductions restored in frequent Phase of duration lower significant study, mice,
and the an X/X scale months, months conducting currently six to changes of ARO-AAT are open-label study, pivotal Phase in study and X histological is months, months which treatment. XX Phase potentially XXXX, assess novel XX design, grading We adaptive a XX clinical clinical an study after SEQUOIA
Day, our R&D candidates. advanced most also the preclinical three During we discussed
being Published hepatitis XX% human ARO-HSD diseases. -- non-alcohol-related sorry, the loss-of-function genetic compared that developed development against reduction with risk being against XX% target HSDXXBXX alcoholic mutation to protection as approximately liver data provides a alcohol to cirrhosis and strong One, indicate and cirrhosis and HSDXXBXX for a non-carriers. treatment in NASH
of expect ARO-HSD for to by the year. file We the CTA end
enter TRiM-enabled renal Two, clear HIFXalpha ARO-HIFX cell against the for treatment first the candidate liver outside clinical as to will trials. a developed carcinoma, a be tissue potential being cell or targeting RCC. This target the
We year. for of the expect end before IND file to the an ARO-HIFX
channel, cystic patients, sodium to And and genetic ENaC, three, fibrosis. epithelial ARO-ENaC activity reduced airway to increased ENaC or dehydration contributes studies being against This as for Human developed target. mucociliary In transport. in filings have fibrosis candidate validated studies the using support cystic first a ENaC will to lung system. TRiM human be are IND-enabling studies inhaled the targeting our CF tissue XXXX. regulatory first ongoing in treat
our expand make that best-in-class strategy for R&D continue we and our and speed. our as detail broadly to product development principles We the execution also guiding discuss organization pipeline
a to achieve different that advances our In We platform system. delivery can that the of TRiM and also genes high simultaneously. knockdown active in of structure together discussed subcutaneous detailed and multiple delivers TRiM levels new dimer that siRNA amenable presented addition, we administration, muscle we second-generation highly is sequences two
dramatically value the the the we detailed This importantly, and companies. a I years. advances R&D gives technical advantage so patients had recommend presentations, of over potential adequate of to many looking get replay The gives Day drive for that significant distinct very potentially informative a provide also important coming to the set website be overview options amount you're can us for increase RNAi about that if treatments. you other diseases over opportunity highly listen us, These and able more to strategic It the on of without Arrowhead. address a number may us to
conference In connection dosing since first Day, included Janssen, million $XX patients last Xb In milestone collaborator, the addition hepatitis REEF-X enormously from our began pivotal with One, combination of in the we the B potentially this chronic to patients triple began the dosing the infection. we our in study. a in Janssen. earned study for study ARO-AAT, start the been accomplishments XXX R&D productive, of payment Two, following. has study, with our Phase patients SEQUOIA call, the in period
airway Conference, ARO-HBV, we called of Four, the clearance formerly and Three, and Cystic also a expanded presented additional on the mucociliary in the NUC. with receiving sheep ARO-ENaC that of showing can normal model therapy, data presented in clearance. this data Fibrosis preserve American HBV impaired capsid the ARO-ENaC additional cohorts Janssen, at assembly, our the sheep clinical doublet on JNJ-XXXX, a triple North data physiology accelerate preclinical mucociliary modulator disease NUC, in JNJ-XXXX, patients and and we JNJ-XXXX of of of case, a collaborator, triplet first
in Bradshaw lot Five, more ARO-ANGX Curt honor late-breaker San concept at I American year we pipeline And to continue expanded to be Martin as Sessions. the include as We've a and new confidence lastly to even a outset begin data and team recently, Association gain CSO, can and we CMO, of and at presented that of call. who tissues. management we our great ARO-APOCX XXXX as we presentations, six, and multiple very rare in have Scientific progress Javier back-to-back the expand this proof our Heart most of clinical extra-hepatic productive made the on introduced
turn With Bruce? that overview, Given. Bruce Dr. to I'd over call the now like to
